Table 1 Risk adjustment model adopted among men with PCa from clinical registries in Victoria
Variable | NCCN |
|---|---|
Low | Clinical T1–T2a stage AND GS 2–6 AND PSA level <10 ng/mL |
Intermediate | Clinical T2b–T2c stage OR GS = 7 OR PSA level 10–20 ng/mL |
High | Clinical T3a stage OR GS 8–10 OR PSA level >20 ng/mL |
Very high (locally advanced) | Clinical T3b–T4 Any T, N1 |
Metastatic | Any T, Any N, M1 |